We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.64 | -0.50% | 127.62 | 128.48 | 127.18 | 128.11 | 2,658,351 | 18:29:15 |
From May 2021 to May 2024
By Colin Kellaher
Merck & Co. on Tuesday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster cancer drug Keytruda in an aggressive type of breast cancer that has an increased risk for recurrence.
The Kenilworth, N.J., drugmaker said the approval covers Keytruda for the treatment of patients with high-risk, early-stage triple-negative breast cancer in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery.
Merck said Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is now approved for 30 indications in the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 06:59 ET (10:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
